Sanofi has announced a €40 million ($42.46 million) investment to enhance its biomanufacturing capabilities at the Lyon Gerland site in France. The initiative aims to bolster the production of Thymoglobulin (antithymocyte globulin [rabbit]), a treatment for kidney transplant rejection, and to localize the manufacturing of type 1 diabetes therapy Tzield (teplizumab). Sanofi says its Lyon […]